rutin and Retinal-Diseases

In a clinically controlled double-blind study it was demonstrated that tri-(hydroxyethyl)-rutin is not capable of significantly improving blood viscosity or one of its constituent factors. On the basis of data from 58 patients, none of whom was under 43 years old, it was possible to show that the substance tested has no favorable influence on plasma viscosity, erythrocyte deformability and aggregation, or on the concentration of plasma proteins which promote aggregation. Thus, in the very group of patients for whom an improvement in blood flow properties by means of oral administration of tri-(hydroxyethyl)rutin had been hoped for, no therapeutic effect could be demonstrated.

Topics: Adult; Anticoagulants; Arteriosclerosis; Blood Proteins; Blood Viscosity; Clinical Trials as Topic; Diabetic Retinopathy; Double-Blind Method; Erythrocyte Aggregation; Erythrocyte Deformability; Erythrocytes; Female; Humans; Hydroxyethylrutoside; Male; Retinal Diseases; Rutin

Topics: Adult; Aged; Aphakia, Postcataract; Clinical Trials as Topic; Cysts; Double-Blind Method; Edema; Female; Humans; Hydroxyethylrutoside; Macula Lutea; Male; Middle Aged; Retinal Diseases; Rutin

Troxerutin, a natural flavonoid guards against oxidative stress and apoptosis with a high capability of passing through the blood-brain barrier. Our aim was to investigate the role of troxerutin in experimentally induced retinal neurodegeneration by modulating the interferon-gamma (IFNγ)-extracellular signal-regulated kinases 1/2 (ERK1/2)-CCAAT enhancer-binding protein β (C/EBP-β) signaling pathway. Three groups of rats (10 each group) were included. Group I (control group), group II (rotenone treated group): the rats were injected subcutaneously with a single rotenone dosage of 3 mg/kg repeated every 48 hours for 60 days to trigger retinal neurodegeneration. Group III (troxerutin-treated group): rats received troxerutin (150 mg/kg/day) by oral gavage 1 hour before rotenone administration. A real-time polymerase chain reaction technique was applied to measure messenger RNA (mRNA) levels of retinal C/EBP-β. Enzyme-linked immunosorbent assay technique was utilized to assay tumor necrosis factor-α (TNF-α), IFNγ, and ERK1/2 levels. Finally, reactive oxygen species (ROS), as well as carbonylated protein (CP) levels, were assessed spectrophotometrically. Improved retinal neurodegeneration by downregulation of C/EBP-β mRNA gene expression, also caused a significant reduction of TNF-α, IFNγ, ERK1/2 as well as ROS and CP levels compared with the diseased group. These findings could hold promise for the usage of troxerutin as a protective agent against rotenone-induced retinal neurodegeneration.

Topics: Animals; CCAAT-Enhancer-Binding Protein-beta; Disease Models, Animal; Down-Regulation; Gene Expression; Hydroxyethylrutoside; Interferon-gamma; Male; MAP Kinase Signaling System; Neurodegenerative Diseases; Protective Agents; Rats; Rats, Wistar; Reactive Oxygen Species; Retinal Diseases; RNA, Messenger; Rotenone; Tumor Necrosis Factor-alpha

High-altitude retinopathy is a very rare ocular disease in our country, which can occur isolately or as a part of high-altitude illness. This paper presents the case of a patient with high-altitude illness and the diagnosis and treatment problems of this case.

Topics: Adult; Altitude Sickness; Anti-Inflammatory Agents; Diagnosis, Differential; Humans; Hydroxyethylrutoside; Male; Prognosis; Retinal Diseases; Risk Factors; Severity of Illness Index; Treatment Outcome; Vasoconstrictor Agents; Vitamins

Topics: Administration, Oral; Diabetic Retinopathy; Drug Evaluation; Fluorescein Angiography; Humans; Hydroxyethylrutoside; Macula Lutea; Macular Degeneration; Retinal Diseases; Retinal Vein Occlusion; Retinal Vessels; Rutin